[go: up one dir, main page]

GB9207479D0 - Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man - Google Patents

Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Info

Publication number
GB9207479D0
GB9207479D0 GB929207479A GB9207479A GB9207479D0 GB 9207479 D0 GB9207479 D0 GB 9207479D0 GB 929207479 A GB929207479 A GB 929207479A GB 9207479 A GB9207479 A GB 9207479A GB 9207479 D0 GB9207479 D0 GB 9207479D0
Authority
GB
United Kingdom
Prior art keywords
man
animals
prevention
treatment
virus infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929207479A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCOTGEN Ltd
Original Assignee
SCOTGEN Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCOTGEN Ltd filed Critical SCOTGEN Ltd
Priority to GB929207479A priority Critical patent/GB9207479D0/en
Publication of GB9207479D0 publication Critical patent/GB9207479D0/en
Priority to ZA932445A priority patent/ZA932445B/en
Priority to EP93908006A priority patent/EP0636182A1/en
Priority to KR1019940703584A priority patent/KR950701386A/en
Priority to NZ251405A priority patent/NZ251405A/en
Priority to PCT/GB1993/000725 priority patent/WO1993020210A1/en
Priority to AU39000/93A priority patent/AU679440B2/en
Priority to JP5517272A priority patent/JPH07508401A/en
Priority to CA002133662A priority patent/CA2133662A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB929207479A 1992-04-06 1992-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man Pending GB9207479D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB929207479A GB9207479D0 (en) 1992-04-06 1992-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
ZA932445A ZA932445B (en) 1992-04-06 1993-04-05 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
EP93908006A EP0636182A1 (en) 1992-04-06 1993-04-06 Antibodies for treatment and prevention of respiratory syncytial virus infection
KR1019940703584A KR950701386A (en) 1992-04-06 1993-04-06 Antibodies For Treatment And Prevention Of Resipiratory Syncytial Virus Infection
NZ251405A NZ251405A (en) 1992-04-06 1993-04-06 Humanised antibody; variable light chain and heavy chain sequences derived from bovine anti-rsv f protein monoclonal antibodies, and cdr peptides therefrom
PCT/GB1993/000725 WO1993020210A1 (en) 1992-04-06 1993-04-06 Antibodies for treatment and prevention of respiratory syncytial virus infection
AU39000/93A AU679440B2 (en) 1992-04-06 1993-04-06 Antibodies for treatment and prevention of respiratory syncytial virus infection
JP5517272A JPH07508401A (en) 1992-04-06 1993-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infections in animals and humans
CA002133662A CA2133662A1 (en) 1992-04-06 1993-04-06 Antibodies for treatment and prevention of respiratory syncytial virus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207479A GB9207479D0 (en) 1992-04-06 1992-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Publications (1)

Publication Number Publication Date
GB9207479D0 true GB9207479D0 (en) 1992-05-20

Family

ID=10713521

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929207479A Pending GB9207479D0 (en) 1992-04-06 1992-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Country Status (9)

Country Link
EP (1) EP0636182A1 (en)
JP (1) JPH07508401A (en)
KR (1) KR950701386A (en)
AU (1) AU679440B2 (en)
CA (1) CA2133662A1 (en)
GB (1) GB9207479D0 (en)
NZ (1) NZ251405A (en)
WO (1) WO1993020210A1 (en)
ZA (1) ZA932445B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6258529B1 (en) * 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
CA2230116A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
FR2758331B1 (en) * 1997-01-14 1999-03-05 Univ Bourgogne NEW MEANS FOR DIAGNOSIS, PREVENTION AND TREATMENT FOR CONTAMINATION OR INFECTIONS WITH MUCOUS TROPISM VIRUSES
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20020004046A1 (en) * 2000-05-03 2002-01-10 Johnson Leslie S. Combination therapy of respiratory diseases using antibodies
US20020018780A1 (en) * 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
FR2970968A1 (en) * 2011-02-01 2012-08-03 Isp Investments Inc NOVEL PEPTIDES INVOLVED IN THE SCF C-KIT SIGNALING PATHWAY AND COMPOSITIONS COMPRISING THE SAME
US9364414B2 (en) 2011-02-01 2016-06-14 Isp Investments Inc. Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes
CA2862979A1 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) * 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10259863B2 (en) 2013-01-11 2019-04-16 The California Institute For Biomedical Research Bovine fusion antibodies
CN111518199A (en) * 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme An antibody that inactivates the human pneumonia virus
US12065484B2 (en) * 2018-09-03 2024-08-20 Pontificia Universidad Catolica De Chile Specific monoclonal antibody against the N antigen of human respiratory syncytial virus (hRSV) useful for treating infection, detection thereof and diagnosis
CN116785427B (en) * 2020-12-18 2024-04-12 珠海泰诺麦博制药股份有限公司 Use of respiratory syncytial virus specific binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396563B1 (en) * 1987-12-23 1993-02-10 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
AU644210B2 (en) * 1990-07-19 1993-12-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
WO1994006448A1 (en) * 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO1994017105A1 (en) * 1993-01-29 1994-08-04 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus

Also Published As

Publication number Publication date
KR950701386A (en) 1995-03-23
AU679440B2 (en) 1997-07-03
NZ251405A (en) 1997-09-22
AU3900093A (en) 1993-11-08
ZA932445B (en) 1995-01-05
CA2133662A1 (en) 1993-10-14
EP0636182A1 (en) 1995-02-01
WO1993020210A1 (en) 1993-10-14
JPH07508401A (en) 1995-09-21

Similar Documents

Publication Publication Date Title
GB9207479D0 (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
GB9019812D0 (en) Novel antibodies for treatment and prevention of infection in animals and man
IL132003A0 (en) Antimicrobial prevention and treatment of human immundeficiency virus and other infectious diseases
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
EP0746322A4 (en) Treatment of alzheimer's disease and modulation of immune system with delta5-androstenes
ZA951831B (en) Vaccine for the prevention of respiratory and reproductive diseases of the pig
PL297849A1 (en) Vaccine against and method of treating the patients infectedwith hiv virus
LTIP863A (en) Aminobenzodiazepines, process for preparing thereof and application for the treatment and prevention of viral diseases
EP0424534A4 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
IL105145A0 (en) Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection
EP0382551A3 (en) Prevention and treatment of herpes virus infections
ZA946489B (en) Novel treatment of upper respiratory tract infections
ZA932303B (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
HK1013665A (en) Antibodies for treatment and prevention of respiratory syncytial virus infection
GB9111885D0 (en) Nerve growth factor for use in the prevention and treatment of viral infections
HK1013831A (en) Novel antibodies for treatment and prevention of infection in animals and man
HU913022D0 (en) Fibroplast increasing factor for treating and preventing virus caused diseases
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
AU4259193A (en) Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
KR960006863B1 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
GB9521008D0 (en) Therapeutic treatment of viral infection in humans and animals
EG20171A (en) Treatment of conditions and disease
IL102021A0 (en) Protein-kinase inhibitors for the treatment of human and animal viral diseases
AU3981093A (en) Preparation useful for prevention and treatment of intestinal infections in animals and human beings